Aberdeen Group plc Purchases 202,318 Shares of Immunovant, Inc. $IMVT

Aberdeen Group plc raised its position in shares of Immunovant, Inc. (NASDAQ:IMVT) by 20.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,184,122 shares of the company’s stock after purchasing an additional 202,318 shares during the quarter. Aberdeen Group plc’s holdings in Immunovant were worth $30,100,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IMVT. Strs Ohio bought a new stake in shares of Immunovant during the 1st quarter valued at $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Immunovant during the 3rd quarter valued at $33,000. PNC Financial Services Group Inc. boosted its holdings in Immunovant by 138.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after buying an additional 1,646 shares during the period. FNY Investment Advisers LLC increased its stake in Immunovant by 100.0% in the 4th quarter. FNY Investment Advisers LLC now owns 4,000 shares of the company’s stock worth $101,000 after buying an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Immunovant by 228.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company’s stock worth $98,000 after buying an additional 4,273 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors.

Insider Transactions at Immunovant

In related news, CTO Jay S. Stout sold 1,977 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $26.03, for a total value of $51,461.31. Following the sale, the chief technology officer owned 197,634 shares in the company, valued at approximately $5,144,413.02. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric Venker sold 14,229 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $24.10, for a total transaction of $342,918.90. Following the completion of the sale, the chief executive officer owned 19,561 shares in the company, valued at $471,420.10. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,286 shares of company stock valued at $498,134 in the last ninety days. Corporate insiders own 1.80% of the company’s stock.

Wall Street Analyst Weigh In

IMVT has been the topic of several research analyst reports. Wolfe Research upgraded Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research report on Tuesday, January 6th. The Goldman Sachs Group increased their target price on Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Truist Financial lifted their target price on Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a report on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Immunovant in a research note on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.00.

Key Headlines Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Management highlights brepocitinib program expansion as a strategic response, signaling a shift of R&D and commercial focus toward the oral JAK/TYK2 asset that could partially offset the batoclimab setback; this gives investors a tangible alternative program to watch for future value creation. Immunovant Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
• Neutral Sentiment: Company released additional corporate materials/slideshow discussing the pipeline and Phase 3 update; these materials provide management context but don’t replace the clinical outcomes that move valuation. Monitor upcoming investor calls or detailed data disclosures for clarification. Slideshow: Brepocitinib and Batoclimab Phase III Data Update
• Negative Sentiment: Batoclimab failed to meet primary endpoints in Phase 3 TED trials — multiple outlets report the late‑stage miss and its immediate negative market implications; this reduces the expected near‑term revenue runway from that program and increases execution risk. Reuters: Treatment for eye disease fails late‑stage trial
• Negative Sentiment: CEO Eric Venker sold 14,229 shares at an average $24.10 (a ~42% reduction in his holdings), a disclosure that can amplify negative sentiment after the clinical setback; insiders selling after disappointing news may concern some investors. SEC Form 4: Insider Sale

Immunovant Price Performance

Shares of Immunovant stock opened at $24.50 on Friday. Immunovant, Inc. has a twelve month low of $12.72 and a twelve month high of $29.25. The business has a 50-day moving average price of $25.75 and a 200-day moving average price of $23.52. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of -9.11 and a beta of 0.67.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings results on Friday, February 6th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11. During the same period in the prior year, the business earned ($0.76) EPS. On average, equities analysts expect that Immunovant, Inc. will post -2.69 EPS for the current fiscal year.

Immunovant Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.